Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCI-779 in Relapsed/Refractory Mantle Cell Lymphoma
NCT00033267Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2002
- Primary completion
- Feb 2006
- Countries
- 1
- Sponsor
- National Cancer Institute
- Modality
- Small Molecules
- Drugs
- temsirolimus
- Conditions
- mantle cell lymphoma (MCL)
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in mantle cell lymphoma (MCL), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 24 weeks. Started Apr 2002; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Treatment
Temsirolimus IV weekly
03
Who it enrols
Patients with histologically confirmed relapsed or refractory mantle cell lymphoma, measurable disease, ECOG 0-2, and adequate organ function.
04
Endpoints
Primary
Objective Response Rate
Secondary
Time to Progression
Overall Survival
Progression-Free Survival
Duration of Response
Toxic Effects
Beyond the preview
Go deeper on NCT00033267.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00033267.